Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
P/E ratio for Inovio Pharmaceuticals, Inc. (INO)
P/E ratio as of 2023: -1.00
According to Inovio Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.00. At the end of 2022 the company had a P/E ratio of -1.29.
P/E ratio history for Inovio Pharmaceuticals, Inc. from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.00 |
| 2022 | -1.29 |
| 2021 | -3.41 |
| 2020 | -6.38 |
| 2019 | -2.70 |
| 2018 | -45.71 |
| 2017 | -45.95 |
| 2016 | -82.46 |
| 2015 | -188.42 |
| 2014 | -180.32 |
| 2013 | -97.16 |
| 2012 | -41.38 |
| 2011 | -42.71 |
| 2010 | -80.86 |
| 2009 | -41.87 |
| 2008 | -21.13 |
| 2007 | -40.88 |
| 2006 | -99.69 |
| 2005 | -33.85 |
| 2004 | -75.94 |
| 2003 | -171.28 |
| 2002 | -22.05 |
| 2001 | -23.95 |
| 2000 | -21.74 |
| 1999 | -122.10 |